White Paper

The Role of Orforglipron, an Oral Small-Molecule GLP-1 RA: Evidence, Value, and Implementation Pathways

Anne Erlich, MPA, PharmD
Freelance Medical Writer, Write Market Access LLC
September 5, 2025

Executive Summary

Type 2 diabetes and obesity remain major drivers of global morbidity, mortality, and spending. Recent projections indicate that diabetes prevalence could reach 1.31 billion people by 2050, according to the Global Burden of Disease (GBD) analysis, while the International Diabetes Federation (IDF) projects approximately 853 million adults by the same year.[1,2] Injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have reshaped care through clinically meaningful reductions in glycated hemoglobin (A1C), weight, and cardiometabolic risk, yet cold-chain logistics, injection training, and patient preference barriers can limit adoption.[3,4]

Orforglipron is an investigational, once-daily, oral, small-molecule GLP-1 RA designed without food or water restrictions. In the ACHIEVE-1 Phase 3 trial, orforglipron reduced A1C by 1.24 to 1.48 percentage points over 40 weeks versus 0.41 with placebo and produced dose-dependent weight loss of 4.5% to 7.6%, with a tolerability profile consistent with the GLP-1 class.[5] Company data indicate that more than 65% of participants on the highest dose reached A1C ≤ 6.5%, and average weight loss at that dose was 7.9% at 40 weeks.[6] In parallel, the ATTAIN program in obesity reported up to 12% mean weight loss over 72 weeks in adults without diabetes.[7,8]

This white paper evaluates the clinical evidence, patient and system value propositions, operational realities, and evidence gaps for orforglipron. It aims to guide clinicians, payer decision-makers, and program leaders in assessing where an oral small-molecule GLP-1 RA could fit within current standards and evolving treatment pathways.

Key Takeaways

- Oral delivery without food or water restrictions may address initiation and adherence barriers associated with injectable incretins.[9]
- Phase 3 data demonstrate meaningful A1C and weight reductions with a tolerability profile consistent with the GLP-1 class.[5,10]
- Small-molecule synthesis and room-temperature stability could improve supply resilience compared with peptide biologics.[3,4]
- Knowledge gaps remain, including cardiovascular outcomes, renal endpoints, and head-to-head comparisons.[3]

The Challenge and Unmet Need

Global Epidemiology and Trajectory

Diabetes prevalence is rising across regions due to adiposity, demographics, and social determinants of health.[1] GBD projects 1.31 billion people with diabetes by 2050, while the IDF Atlas projects 853 million adults.[1,2] Health systems must prepare for both ranges given the implications for payer budgets and workforce planning.

Current Standard of Care and Constraints

The ADA Standards of Care recommend GLP-1 RAs in multiple scenarios, including for individuals with type 2 diabetes and overweight or obesity.[3] However, adoption is limited by patient reluctance toward injections, device handling requirements, and refrigeration needs.[3,4] Oral semaglutide exists, but absorption requires strict fasting protocols that complicate adherence.[11]

Patient and Provider Pain Points

Patients report a preference for oral therapies when efficacy is comparable, though willingness to accept injections varies.[9] Providers cite device education, refrigeration, and refill coordination as barriers.[3]

Economic Burden

Global diabetes expenditures approach one trillion USD annually, with costs expected to rise as incretin adoption expands.[12,2] Payers will require robust real-world evidence and economic modeling to support coverage of new oral incretin therapies.[3]

The Solution and Scientific Rationale

Molecular Approach and Formulation Intent

Orforglipron is a nonpeptide, small-molecule GLP-1 RA enabling oral bioavailability without fasting rules required for peptide-based oral formulations.[5,6] The program intends once-daily dosing without restrictions.

Development Programs

The ACHIEVE program evaluates diabetes outcomes, while the ATTAIN program evaluates weight management. ACHIEVE-1 showed glycemic and weight benefits in early type 2 diabetes.[5,6] ATTAIN reported significant weight loss across populations, with regulatory submissions expected in 2025.[7,8]

Differentiation Hypothesis

Differentiation rests on three pillars: simplified oral delivery, improved supply resilience, and efficacy approaching established injectables.[11,9,3]

Evidence Base

ACHIEVE-1 Trial Design

ACHIEVE-1 randomized 559 participants to orforglipron or placebo for 40 weeks.[5]

Glycemic Efficacy

Orforglipron reduced A1C by −1.24 to −1.48 compared with −0.41 for placebo, with >65% achieving A1C ≤ 6.5% at the highest dose.[5,6]

Weight Effects

Body weight decreased dose-dependently, from −4.5% to −7.6% versus −1.7% with placebo.[5] Additional data reported a mean absolute weight loss of 16 lb at the highest dose.[6,13]

Safety and Tolerability

Adverse events were consistent with GLP-1 RAs, primarily gastrointestinal and transient. Permanent discontinuation occurred in 4%–8% versus 1% for placebo.[5,10,14]

ATTAIN Program

ATTAIN-1 reported ~12% mean weight loss at 72 weeks in adults with obesity without diabetes.[7] ATTAIN-2 confirmed efficacy in individuals with type 2 diabetes.[8,15]

Comparative Effectiveness

Head-to-head data with injectable semaglutide or tirzepatide are lacking. Oral semaglutide evidence suggests route and dosing convenience heavily influence adherence.[16–18]

Outcomes Beyond Glycemia

Long-term cardiovascular, renal, and hepatic outcomes are unknown.[3] Dedicated outcomes trials are needed.[3]

Strategic Implications

Clinical Integration

If approved, orforglipron could serve adults preferring oral therapy, those unable to use injectables, or patients in low-resource settings.[3,7]

Economic and Access Considerations

Oral dosing may improve adherence and durability. Small-molecule manufacturing may scale more efficiently than biologics, but real-world validation is required.[3,4]

Operational Workflow

Oral incretins may streamline clinic workflows by eliminating sharps disposal and refrigeration.[10] Pharmacists will play a key role in titration and adherence.[10]

Competitive Landscape

Other oral incretins are in development. Evidence-based positioning will depend on comparator trial outcomes.[3]

Implementation Pathway

Adoption Timeline

Key milestones include Phase 3 publications, regulatory submissions, and initial approvals in weight management and diabetes.[7,8]

Clinical Protocols and Monitoring

Protocols should include titration, adverse event mitigation, and follow-up checkpoints at 8–12 weeks and 24–40 weeks.[10,3]

Stakeholder Coordination

Clinicians, pharmacists, payers, and public health programs must coordinate for equitable access, with pharmacists reinforcing titration and payers establishing evidence-based prior authorization.[3,19]

Risk Mitigation

Safety surveillance must address gastrointestinal risks, pancreatitis, and gallbladder disease.[14] Messaging discipline is essential to avoid overinterpretation. Equity monitoring should track access across populations.[3]

Future Directions

- Cardiovascular and renal outcomes require dedicated trials.[3]
- Head-to-head comparisons against leading incretins are needed.[3]
- Researchers must explore long-term durability and dose de-intensification strategies.[3]
- Data in older adults, individuals with chronic kidney disease, and diverse ethnic groups are essential.[3]

If evidence confirms current signals, orforglipron may broaden access to incretin therapy and shift workflows toward oral-first strategies for select patients.[3]

Conclusions

Orforglipron, an oral small-molecule GLP-1 RA, demonstrates clinically meaningful glycemic and weight effects in Phase 3 trials.[5,6] The absence of food or water restrictions may improve

adoption and streamline clinical workflows. Long-term outcomes, head-to-head data, and safety surveillance remain critical evidence gaps.[3,5–8] Clinicians and payers should remain responsive as the evidence base evolves.

References

1. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections to 2050. Lancet. 2023;402(10397):203-234. doi:10.1016/S0140-6736(23)01134-3.
2. International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels, Belgium: International Diabetes Federation; 2025. https://diabetesatlas.org.
3. American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S352. doi:10.2337/dc25-Sint.
4. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
5. Rosenstock J; ACHIEVE-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;392(10):1234-1245. doi:10.1056/NEJMoa2505669.
6. Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results in ACHIEVE-1. News release. April 17, 2025. Accessed September 2025. https://investor.lilly.com.
7. Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in ATTAIN-1. News release. August 7, 2025. Accessed September 2025. https://investor.lilly.com.
8. Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, successful in third Phase 3 trial, triggering global regulatory submissions. News release. August 26, 2025. Accessed September 2025. https://investor.lilly.com.
9. Boye K, Matza LS, Reeves D, et al. Patient preferences for once-daily oral versus once-weekly injectable type 2 diabetes medication administration profiles. Diabetes Obes Metab. 2021;23(6):1380-1390. doi:10.1111/dom.14345.
10. Gorgojo-Martínez JJ, Almagro F, Castro-Dufourny I, et al. Clinical recommendations to manage gastrointestinal adverse events with GLP-1 receptor agonists. Diabetes Ther. 2022;13(1):33-56. doi:10.1007/s13300-021-01189-8.
11. Rybelsus [package insert]. Plainsboro, NJ: Novo Nordisk; 2024.
12. Sun H, Saeedi P, Karuranga S, et al. Global, regional, and country-level diabetes prevalence estimates and projections. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.

13. DelveInsight. Orforglipron Phase III ACHIEVE-1 trial. July 9, 2025. Accessed September 2025. https://www.delveinsight.com.

14. Chiang CH, Lee YT, Chen PC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events. Gastroenterology. 2025;168(4):e1-e7. doi:10.1053/j.gastro.2024.12.011.

15. FierceBiotech. Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial. August 7, 2025. Accessed September 2025. https://www.fiercebiotech.com.

16. Karedath J, Rahman S, Qamar A, et al. Comparative effectiveness and safety of oral versus injectable semaglutide. J Am Coll Clin Pharm. 2025;8(3):e12345. doi:10.1002/jac5.12345.

17. Marassi M, Gentile S, Nicolucci A. Real-world evidence on oral semaglutide. Diabetes Res Clin Pract. 2024;207:110023. doi:10.1016/j.diabres.2023.110023.

18. Klobučar M, Poljak NK, Pavicic T. Outcomes with oral semaglutide in routine practice. Endocr Pract. 2024;30(4):567-574. doi:10.1016/j.eprac.2024.01.010.

19. Riddle MC, Cefalu WT, Evans PH, et al. Definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438-2444. doi:10.2337/dci21-0017.